Case Study 1
Title:
Clinical Case Study: Evaluating the Efficacy of the Antioxidant, Spermizz, on Oligospermia and
Male Infertility in the Context of Obesity
Date: 09-06-2022
Author: Dr. Monika
Background
Obesity, with its increasing prevalence, has come under the spotlight for its broad array of
associated health complications. In the realm of male reproductive health, obesity has been
reported to significantly increase the risk of infertility. The National Institutes of Health states that
men with a BMI over 30 are at a 50% greater risk for being infertile compared to those within the
normal weight range. Notably, obesity is often linked with oligospermia - a condition
characterized by a lower-than-normal sperm count, thus amplifying the risks of male infertility.
This case study revolves around the potential therapeutic impact of Spermizz, an antioxidant, on
male infertility associated with oligospermia in the context of obesity.
Presentation
A 27-year-old male with a Body Mass Index (BMI) of 32, suggesting obesity, presented with an
inability to conceive persisting for two years. The ongoing fertility issue had become a significant
source of distress for him and his partner.
Clinical History
The patient has been grappling with obesity for a decade, a condition that poses adverse
impacts on male fertility. Despite his health condition, he is not currently on any medications.
Evaluation and Diagnosis
A comprehensive semen analysis revealed oligospermia, with a total sperm count of 35 million,
lower than the average range. His sperm vitality and total motility stood at 50%, with a
progressive motility of 27% and normal morphology of 4%. These combined results led to a
diagnosis of male infertility with oligospermia.
Treatment
To tackle this complex diagnosis, the patient was prescribed Spermizz, with a dosage of one
tablet a day for a duration of 2.5 months.
Follow-Up
The evaluation of the treatment's effectiveness was conducted 90 days after initiation. There
were significant improvements in all the examined outcomes. The semen volume rose from 1.2
mL to 1.5 mL. The sperm concentration increased by 40%, improving from 25 x 10 ⁶/mL to 35 x
10⁶/mL. The total sperm count witnessed a increase of approximately 11%, from a baseline of 35
x 10⁶ to 39 x 10⁶.
More impressively, both sperm vitality and total motility exhibited a significant increase of 24%,
from a baseline of 50% to 62% after the treatment. The progressive motility showed an
improvement of 19%, from 27% to 32%. Meanwhile, the sperm morphology remained consistent
at 4%.
Conclusion
Despite the challenges posed by oligospermia and obesity, this case study provides compelling
evidence supporting the potential effectiveness of Spermizz in improving male fertility. It suggests
that Spermizz could offer an innovative and efficacious therapeutic option, even in the context
of obesity, to significantly enhance sperm parameters. Consequently, Spermizz could be
considered an essential component in the management of male infertility associated with
obesity and oligospermia.
Case Study 2
Title: Clinical Case Study: Evaluating the Efficacy of the Antioxidant, Spermizz, on Male Infertility
Date: 23-06-2022
Author: Dr. Monil
---
Background
Recent demographic research conducted in Massachusetts underscores a prevailing problem
in male aging: approximately 52% of males are likely to suffer from erectile dysfunction (ED) — a
condition characterized by the inability to achieve or sustain an erection adequate for
satisfactory sexual performance. ED not only manifests physically, but it also imposes substantial
psychological burdens, such as anxiety, depression, and diminished self-esteem, thereby
affecting the overall quality of life.
The focus on discovering effective treatments for ED and related conditions like infertility stems
from the essential role that sexual health plays in maintaining healthy and intimate relationships,
especially for young couples.
Presentation
The subject of this case study is a 34-year-old married male. He presented with a set of symptoms
persisting for the past 3 years, including the inability to conceive, reduced libido, and difficulties
in achieving and maintaining an erection. These symptoms are typical of male factor infertility,
where ED plays a significant role.
Clinical History
The medical history showed anxiety disorder diagnosed two years prior. His current treatment
regimen includes the anxiolytic, Clonazepam, and the non-selective beta-blocker, Propranolol.
These medications, while effective in managing his anxiety, could potentially contribute to his ED
and consequent infertility, as they are known to interfere with sexual function.
Evaluation and Diagnosis
Upon presentation, a comprehensive physical and systemic evaluation was conducted. Both
assessments revealed no significant abnormalities. Further investigations included hematological
tests, a renal stone analysis (RSA), and an ultrasonography (USG), all of which yielded results
within normal limits. An examination of Mr. Kumar's partner showed no pathological findings.
Considering the patient’s primary complaints, a baseline semen analysis was conducted. The
results, along with the findings from his medical evaluation, resulted in a diagnosis of primary
male infertility attributed to erectile dysfunction. The treatment was initiated with the oral
administration of Spermizz, an antioxidant, One tablet a day prescribed for two months.
Follow-Up
The evaluation of therapeutic effectiveness was assessed via a follow-up semen analysis three
months after starting Spermizz. The results were promising: the total sperm count showed a
significant increase of approximately 10%, rising from a baseline of 35 million/mL to 40 million/mL.
A notable improvement was observed in total sperm motility — a key factor for successful
fertilization.
This parameter showed a significant 40% increase, improving from 50% at baseline to 70% post-
treatment. This substantial increase in motility significantly boosts the chances of successful
fertilization. The sperm morphology remained stable at 4%.
Throughout the treatment period, the patient reported no adverse effects, which speaks about
the safety and tolerability profile of Spermizz.
Conclusion
In conclusion, this case study provides promising evidence supporting the potential effectiveness
of Spermizz as an intervention for improving male fertility. Particularly in cases associated with
erectile dysfunction, Spermizz may offer an innovative and effective therapeutic option.
Spermizz can be considered as a vital cog in the management of male infertility.
Case 3
Title: Clinical Case Study: Assessing the Efficacy of the Antioxidant, Spermizz, on Male
Infertility Related to Asthenospermia and Alcoholism
Date: 11-07-2022
Author:
Background
Recent demographic research shows that 50% of infertility cases can be traced to male
factors. Among these, asthenospermia, a condition where the sperm mobility is
insufficient to reach the oocyte, is a common issue. Alcohol consumption is known to
affect semen quality negatively, potentially leading to conditions like asthenospermia.
This case study examines the impact of the antioxidant, Spermizz, on male infertility,
especially where asthenospermia is a contributory factor.
Presentation
The subject is a 35-year-old male who has been unsuccessful in conceiving for two
years. His partner has a history of Polycystic Ovary Syndrome (PCOS), a condition that
can also contribute to fertility [Link] patient reported alcohol consumption of 40-
80ml daily but was a non-smoker.
Investigation and Diagnosis
A preliminary Semen analysis was conducted in which the count and progressive
motility were both below the normal range, 20 million and 15%, respectively, indicative
of asthenospermia. In light of these findings, the couple's infertility was attributed to
asthenospermia in the subject and PCOS in his partner.
Treatment
The patient was prescribed Spermizz, to be taken twice daily for three months.
Follow-Up
In the 90-day follow-up after treatment with Spermizz, significant improvements in sperm
motility parameters were noted. The total sperm motility increased from 20% to 38%,
signifying a 90% increase from the baseline. Additionally, progressive motility improved
from 15% to 38%, which represents a 153% increase. These increases are nearly two-fold
and over two-fold respectively, signifying a significant improvement in the subject's
asthenospermia condition. In contrast, the semen volume and sperm concentration
remained stable at 1.5mL and 20 million, respectively. Thus, the treatment's efficacy was
primarily seen in improving sperm motility parameters, which are crucial for fertilization.
Conclusion
This case study provides promising evidence that supports the potential effectiveness of
Spermizz in cases of male infertility related to asthenospermia, even in patients with
daily alcohol consumption. Despite the patient's continued alcohol consumption, an
almost twofold increase in total and progressive sperm motility post-treatment was a
significant improvement.
Spermizz can potentially be considered as an integral part of the management of male
infertility associated with asthenospermia. Spermizz can be explored along with
potential synergies with lifestyle modifications.
Case Study 4
Clinical Case Study: A Comprehensive Evaluation of the Antioxidant, Spermizz, in Treating Male
Infertility Coupled with Metabolic Disorders and Oligoasthenoteratozoospermia.
Date: 13-09-2022
Author: Dr Monil
Background
Infertility has been a significant concern across the globe, with male infertility constituting
approximately half of all fertility issues. When combined with metabolic disorders like obesity,
diabetes mellitus (DM), and hypertension (HT), the problem of infertility becomes far more
complex and challenging to address. A common clinical condition contributing to male infertility
is oligoasthenoteratozoospermia, a disorder characterized by three major sperm abnormalities:
oligozoospermia (low sperm count), asthenozoospermia (poor sperm movement), and
teratozoospermia (abnormal sperm shape). Addressing these conditions effectively requires a
targeted therapeutic approach. This case study aims to explore the potential efficacy of
Spermizz, an antioxidant supplement, in improving the sperm parameters in cases with
oligoasthenoteratozoospermia and metabolic disorders.
Presentation
A 40-year-old male, presented with a longstanding issue of infertility, persisting for two years into
his second marriage. This problem was causing significant stress and distress, impacting his
overall quality of life and relationship with his partner.
Clinical History
In addition to infertility, the patient has a history of obesity, diabetes mellitus, and hypertension -
conditions known to potentially impact male fertility. He also has a history of alcohol
consumption, another possible negative influence on fertility. His current medical management
includes oral hypoglycemic and anti-hypertensive medications to manage his co-morbid
conditions.
Evaluation and Diagnosis
A comprehensive semen analysis revealed a constellation of sperm abnormalities, indicating
oligoasthenoteratozoospermia. His sperm count was considerably low, the motility was
compromised, and a significant portion of his sperm showed abnormal morphology. Meanwhile,
his wife was found to have a poor ovarian reserve along with irregular menstrual cycles, further
complicating their fertility concerns.
Treatment
Based on the complex diagnosis, an integrated approach was taken for treatment. The patient
was prescribed Spermizz, with a dosage of two tablets a day for a duration of three months, in
addition to his ongoing medications.
Follow-Up
The treatment's efficacy was evaluated 90 days post-initiation. There were remarkable
improvements in all the evaluated outcomes. The total sperm count saw an increase of around
33%, from a baseline of 15 x 10⁶ to 20 x 10⁶. Sperm vitality also improved significantly, showing a
200% increase from 5% to 15%. The most notable improvement was observed in the total motility,
which increased from 5-7% at baseline to 25% post-treatment. This represents at least a 250%
increase, which significantly enhances the chances of successful fertilization.
Conclusion
Despite the complexities presented by the co-morbid metabolic conditions and
oligoasthenoteratozoospermia, this case study suggests that Spermizz shows promise as an
effective intervention for male infertility. In the backdrop of metabolic disorders, Spermizz could
offer an innovative and effective therapeutic option that significantly improves the sperm
parameters. It emphasizes that Spermizz could be an integral component in the management
strategy of male infertility with underlying metabolic disorders.
Case 5
Title: Clinical Case Study: Evaluating the Efficacy of the Antioxidant, Spermizz, on
Asthenospermia and Male Infertility
Date: 06-01-2023
Author: Dr. Monil
Background
The widespread issue of male infertility has been increasingly affecting a multitude of
couples globally. A key contributor to this prevalent concern is asthenospermia - a
condition characterized by diminished sperm motility, which inevitably reduces the
odds of successful fertilization. In fact, based on a study conducted by the World Health
Organization, it's estimated that between 2.5% and 12% of men worldwide could
potentially be grappling with reduced sperm motility, a defining characteristic of
asthenospermia. In this light, the present case study delves into exploring the potential
therapeutic potential of Spermizz, an antioxidant, as a means to counteract male
infertility linked with asthenospermia.
Presentation
A 40-year-old male, who had been facing challenges in conceiving for the past four
years, presented himself for evaluation. The ongoing struggle to conceive has been a
recurrent source of emotional strain and can tend to affect the quality of life and
physical intimacy between partners.
Clinical History
The patient has a history of occasional alcohol use but is a non-smoker. No other
significant medical or lifestyle issues are noted.
Evaluation and Diagnosis
A detailed semen analysis was conducted on the observed sperm concentration was
15 million (within the normal range), but the progressive motility was 23%, which was
significantly lower than the average range (52%). This combination of findings led to a
diagnosis of male infertility associated with asthenospermia.
Treatment
In response to this diagnosis, the patient was prescribed Spermizz, with a dosage of two
times a day for a duration of three months.
Follow-Up
After 90 days of treatment initiation, a remarkable improvement was observed in all
measured parameters. The semen volume remained consistent at 1.5 mL. The sperm
concentration showed a significant improvement, increasing from 15 million to 22
million. The total sperm count also increased from 35 million to 40 million.
Moreover, total motility showed an improvement of 25%, increasing from 40% to 50%.
The progressive motility doubled, showing a significant improvement from 23% to 50%,
the sperm morphology remained consistent at 4%.
Conclusion
Despite the complexities associated with asthenospermia, this case study illustrates the
potential efficacy of Spermizz in addressing male infertility. The improvements observed
in sperm concentration, total count, and motility suggest Spermizz can be a useful
therapeutic approach in managing male infertility associated with asthenospermia.
Future studies may build upon these findings to further validate Spermizz's therapeutic
benefits.
RAW DATA
CASE STUDY 1
ANTIOXIDANT (SPERMIZZ) USER EXPERIENCE STUDY
Patient ID : 1004182 Date : 09-06-22
Mr. Rajan Cheek
Age : 27 Years
Gender : Male BMI : 32
PRESENTATION
[Link] Sign & Symptoms Grade , if any Duration
Inable to conceive 1 2yrs
INVESTIGATIONS
[Link] Test Date Observed value Normal Value
1 Routine Semen 2/6/22 [Link] 15 Million
Analysis
[Link] count 35 Million
Motility 50%
Morphology 4%
DIAGNOSIS
Final Diagnosis : Stage / Grade :
10 infectility with Oligo Speemia
OUTCOMES MEASURED BASELINE 90 DAYS
Semen Volume (mL) 1.2mL 1.5mL
Sperm Concentration (10⁶/mL) 25 35
Total Sperm Count (10⁶) 35 39
Sperm Vitality (%) 50% 62%
Total Motility (%) 50% 62%
Progressive Motility (%) 27% 32%
Normal Morphology (%) 4% 4%
Others:
Comments on Observation :
To Spermiz improved oligo speemia of patient .
CO-MORBIDITIES
[Link] Diseases Stage / Grade Duration On Medication
Yes / No
1 Obesity 10 yr No
CONCOMITANT
MEDICATION
[Link] Drug Dose Route Frequency Duration
Nil
TREATMENT GIVEN
Drug Dose Treatment Duration
Baseline (Day 0) [Link] 1 Tab 2.5 months
90 Days
I DR. Monika confirmed that I have reviewed the case report form and confirm to the
best of my knowledge, the information contained within is accurate and complete.
CASE STUDY 2
ANTIOXIDANT ( SPERMIZZ) USER EXPERIENCE STUDY
Patient ID : 1018472 Date : 23-06-22
Mr Vipul Kumar
Age : 34 Years
Gender : Male BMI :
PRESENTATION
[Link]. Signs & Symptoms Grade, if any Duration
Inability to conceive 3 years
Low Libido ,
Difficulty in erection
INVESTIGATION
[Link]. Test Date Observed Value Normal Value
1 R.S.A (9/6/22) WNL
2 USG Scrotum (10/6/22) WNL
Normal Study
DIAGNOSIS
Final Diagnosis : Stage / Grade :
10 Infertility Male Factor
(Erectile dysfunction)
OUTCOMES MEASURED BASELINE 90 DAYS
Semen Volume (mL) 1.5mL 1-5-2mL
Sperm Concentration (10⁶/mL) 32 35
Total Sperm Count (10⁶) 35 40
Sperm Vitality (%) - -
Total Motility (%) 50% 70%
Progressive Motility (%) 50% 68%
Normal Morphology (%) 4% 4%
Others:
Comments on Observation :
Improved Semen Parameters
CO-MORBIDITIES
[Link]. Disease/ Disorder Stage / Grade Duration On Medication
Yes /No
Anxiety disorder 4-5 Years Yes
1
CONCOMITANT MEDICATIONS
[Link]. Drug Dose Route Frequency Duration
1 Pobloelus 3 cups Oral Once Daily 2 Years
(Propranolol)
TREATMENT GIVEN
Drug Dose Treatment Duration
Baseline (Day 0) [Link] 1 tab once daily 2 Months
90 Days
I DR. Monil confirmed that I have reviewed the case report form and confirm to the best
of my knowledge, the information contained within is accurate and complete.
CASE STUDY 3
ANTIOXIDANT ( SPERMIZZ) USER EXPERIENCE STUDY
Patient ID : Date : 11-07-22
Mr Manjeet Singh
Age : 35Years
Gender : Male BMI :
PRESENTATION
[Link]. Signs & Symptoms Grade, if any Duration
P. A2 2 infertilityP A 2
infertility
INVESTIGATION
[Link]. Test Date Observed Value Normal Value
Wife PCOD Count 20 millions
Husband 13-6-22 Motility 20 % ( )
Semen Analysis Progressive 15 %
Motility
DIAGNOSIS
Final Diagnosis : Stage / Grade :
P.A2 2 infertility with PCOD (wife) and
Asthenospermia
OUTCOMES MEASURED BASELINE 90 DAYS
Semen Volume (mL) 1.5mL 1.5mL
Sperm Concentration (10⁶/mL) 20 million 20 million
Total Sperm Count (10⁶) 25 35
Sperm Vitality (%) - -
Total Motility (%) 20% 38%
Progressive Motility (%) 15% 38%
Normal Morphology (%) 4% 4%
Others:
Comments on Observation :
CO-MORBIDITIES
[Link]. Disease/ Disorder Stage / Grade Duration On Medication
Yes /No
Alcoholism +
40-80ml Daily
Non Smoker
CONCOMITANT MEDICATIONS
[Link]. Drug Dose Route Frequency Duration
Nil
TREATMENT GIVEN
Drug Dose Treatment Duration
Baseline (Day 0) [Link] BD 3 months
90 Days
I DR. Monil confirmed that I have reviewed the case report form and confirm to the best
of my knowledge, the information contained within is accurate and complete.
CASE STUDY 4
ANTIOXIDANT ( SPERMIZZ) USER EXPERIENCE STUDY
Patient ID : 1764821 Date : 13-09-22
Mr Tej Veer
Age : 40Years
Gender : Male BMI :
PRESENTATION
[Link]. Signs & Symptoms Grade, if any Duration
2 infertility 2 yr
(2nd Marriage)
INVESTIGATION
[Link]. Test Date Observed Value Normal Value
Husband semen 10/9/22 Count
analysis
4.5 million ( )
Wife - delayed
5% ( )
Cycle , poor ovarian
reserve Normal forms
2% ( )
DIAGNOSIS
Final Diagnosis : Stage / Grade :
10 infertility with oligoasthenoterato
zoospermia with poor ovarian reserve in wife
OUTCOMES MEASURED BASELINE 90 DAYS
Semen Volume (mL) 0.5 - 1 mL 1-1.5 mL
Sperm Concentration (10⁶/mL) 10 x 100 12
Total Sperm Count (10⁶) 15 x 100 20 x 100
Sperm Vitality (%) 5% 15 %
Total Motility (%) 5-7% 25 %
Progressive Motility (%) 5-1% 25 %
Normal Morphology (%) 2% 3%
Others:
Comments on Observation :
CO-MORBIDITIES
[Link]. Disease/ Disorder Stage / Grade Duration On Medication
Yes /No
Obesity +
DM + HT (Husband)
Alcoholic +
CONCOMITANT MEDICATIONS
[Link]. Drug Dose Route Frequency Duration
1 Oral
Hypoglycemic
drug
2 Anti hypertensive
TREATMENT GIVEN
Drug Dose Treatment Duration
Baseline (Day 0) [Link] BD 3 months
90 Days
I DR. Monil confirmed that I have reviewed the case report form and confirm to the best
of my knowledge, the information contained within is accurate and complete.
CASE STUDY 5
ANTIOXIDANT ( SPERMIZZ) USER EXPERIENCE STUDY
Patient ID : Date : 06-01-23
Dilraj Singh
Age : 40Years
Gender : Male BMI :
PRESENTATION
[Link]. Signs & Symptoms Grade, if any Duration
10 infertility 4 yrs
INVESTIGATION
[Link]. Test Date Observed Value Normal Value
Semen analysis 4-01-23 15 Million - (N)
Motile 40 % -(N)
Progression 23% ( )
Non motile 52%
DIAGNOSIS
Final Diagnosis : Stage / Grade :
Asthenospermia
OUTCOMES MEASURED BASELINE 90 DAYS
Semen Volume (mL) 1- 1.5 mL 1.5 mL
Sperm Concentration (10⁶/mL) 15 Million 22Miliion
Total Sperm Count (10⁶) 35 Million 40 Million
Sperm Vitality (%) - -
Total Motility (%) 40% 50 %
Progressive Motility (%) 23% 50%
Normal Morphology (%) 4% 4%
Others:
Comments on Observation :
CO-MORBIDITIES
[Link]. Disease/ Disorder Stage / Grade Duration On Medication
Yes /No
Occasionally
Alcoholism
Non smoker
CONCOMITANT MEDICATIONS
[Link]. Drug Dose Route Frequency Duration
TREATMENT GIVEN
Drug Dose Treatment Duration
Baseline (Day 0) [Link] BD 3 months
90 Days
I DR. Monil confirmed that I have reviewed the case report form and confirm to the best
of my knowledge, the information contained within is accurate and complete.
